Fig. 4

miR-128 function before EHT is conserved in hPSCs.

a, Schematic of HSPC development in vitro using hPSCs and treated as indicated with antagomiR-128 or scramble miR as control at different cell stages. b,c, Colony-forming cell assay quantification of erythroid (BFU-E, CFU-E) and myeloid (CFU-M, CFU-G, CFU-GM) of HOXA+ programme (definitive haematopoiesis) during stage 1 (b) or stage 2 (c). d, Colony-forming cell quantification of erythroid (Ery-P, BFU-E) and myeloid (CFU-M, CFU-G, CFU-GM) of HOXA/low− programme (primitive haematopoiesis) (three independent experiments). All Quantification are represented with mean ± s.e.m. NS, not significant; P > 0.05, **P ≤ 0.01, ****P ≤ 0.0001. HE, haemogenic endothelium; CFC, colony-forming cell; BFU-E, burst-forming units erythroid; CFU-E, colony-forming units of erythroid; CFU-G, colony-forming units of granulocyte; CFU-M, colony-forming units of myeloid; CFU-GM, colony-forming units of mixed granulocyte/myeloid.